Do cost-sharing and entry deregulation curb pharmaceutical innovation?

This paper examines the role of both cost-sharing schemes in health insurance systems and the regulation of entry into the pharmaceutical sector for pharmaceutical R&D expenditure and drug prices. The analysis suggests that both an increase in the coinsurance rate and stricter price regulations...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of health economics Vol. 32; no. 5; pp. 881 - 894
Main Author:	Grossmann, Volker
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01-09-2013 Elsevier Sequoia S.A
Subjects:	Coinsurance Control Cost engineering Cost Sharing Deregulation Drug and Narcotic Control - legislation & jurisprudence Drug Costs Drug Discovery Drug Industry - legislation & jurisprudence Economics Entry deregulation Expenditures Health Health administration Health insurance Labor Models, Statistical Patent breadth Patents as Topic Pharmaceutical industry Pharmaceutical innovation Pharmaceuticals Price regulations Productivity Research & development expenditures Studies United States United States Cost-sharing Health insurance Patent breadth I10 Entry deregulation L10 Pharmaceutical innovation O30
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!